NO20073710L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO20073710L
NO20073710L NO20073710A NO20073710A NO20073710L NO 20073710 L NO20073710 L NO 20073710L NO 20073710 A NO20073710 A NO 20073710A NO 20073710 A NO20073710 A NO 20073710A NO 20073710 L NO20073710 L NO 20073710L
Authority
NO
Norway
Prior art keywords
glycogen phosphorylase
chemical connections
activity
diabetes
consequently
Prior art date
Application number
NO20073710A
Other languages
English (en)
Inventor
Paul Robert Owen Whittamore
Craig Johnstone
Alan Martin Birch
Iain Simpson
Alleyn Plowright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0502465A external-priority patent/GB0502465D0/en
Priority claimed from GB0502466A external-priority patent/GB0502466D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20073710L publication Critical patent/NO20073710L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

(1) En forbindelse med formel (1) eller et farmasøytisk akseptabelt salt: har glykogen-fosforylase-hemmende aktivitet og har følgelig verdi ved behandling av sykdomstilstander forbundet med øket glykogen-fosforylase-aktivitet, så som type 2 diabetes. Fremgangsmåter for fremstilling av forbindelser og farmasøytiske preparater inneholdende dem er beskrevet. ?? ?? ?? ?? 89
NO20073710A 2005-02-05 2007-07-18 Kjemiske forbindelser NO20073710L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0502465A GB0502465D0 (en) 2005-02-05 2005-02-05 Chemical compounds
GB0502466A GB0502466D0 (en) 2005-02-05 2005-02-05 Chemical compounds
PCT/GB2006/000349 WO2006082401A1 (en) 2005-02-05 2006-02-02 Chemical compounds

Publications (1)

Publication Number Publication Date
NO20073710L true NO20073710L (no) 2007-08-31

Family

ID=36178184

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073710A NO20073710L (no) 2005-02-05 2007-07-18 Kjemiske forbindelser

Country Status (11)

Country Link
US (1) US20100137397A1 (no)
EP (1) EP1848721A1 (no)
JP (1) JP2008528667A (no)
KR (1) KR20070107108A (no)
AU (1) AU2006210719A1 (no)
BR (1) BRPI0606838A2 (no)
CA (1) CA2595835A1 (no)
IL (1) IL184628A0 (no)
MX (1) MX2007009438A (no)
NO (1) NO20073710L (no)
WO (1) WO2006082401A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2010085811A2 (en) 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
DK2590595T3 (en) 2010-07-09 2015-12-07 Highlife Sas Transcatheter atrioventricular heart valve prosthesis
US20240190809A1 (en) * 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021831D0 (en) * 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
GB0318463D0 (en) * 2003-08-07 2003-09-10 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
BRPI0606838A2 (pt) 2010-02-09
AU2006210719A1 (en) 2006-08-10
US20100137397A1 (en) 2010-06-03
IL184628A0 (en) 2007-12-03
CA2595835A1 (en) 2006-08-10
WO2006082401A1 (en) 2006-08-10
KR20070107108A (ko) 2007-11-06
EP1848721A1 (en) 2007-10-31
JP2008528667A (ja) 2008-07-31
MX2007009438A (es) 2007-08-16

Similar Documents

Publication Publication Date Title
NO20074872L (no) Pyrazoler
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20083863L (no) Pyrazoler som 11-beta-hsd-1
NO20082709L (no) Kjemiske forbindelser
NO20081052L (no) GSK-3 inhibitorer
NO20073719L (no) Kjemiske forbindelser
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
NO20074703L (no) Antibakterielle piperidinderivater
NO20072608L (no) Biaryloksymetylarenkarboksylsyrer
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
NO20081211L (no) Xantinderivater som selektive HM74A agonister
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler
NO20061743L (no) Kinazolinderivater
NO20091599L (no) Kjemiske forbindelser
NO20091683L (no) Kjemiske forbindelser
NO20070566L (no) Azin-karboksamider som antikreftmiddel
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO341617B1 (no) Dihydropyrazolpyrimidinonderivater, deres anvendelse i terapi og til behandling av kreft, deres anvendelse for fremstilling av et medikament, og for anvendelse som strålingssensibilisator, farmasøytisk sammensetning derav, samt et kombinert preparat for administrering ved behandling av kreft.
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20082445L (no) Neuropeptid-2 reseptor-agonister
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
NO20073367L (no) Makrolider
NO20060947L (no) β d-krystalinsk form av ivabradin-hydroklorid, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application